1005407-63-5

Upstream product

• 111-87-5 octanol 
• 67515-55-3 4-fluoro-3-(trifluoromethyl)benzoic acid 

Downstream Products

• 1005408-96-7 (S)-tert-butyl 2,2,4-trimethyl-4-(3-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-3-oxopropanoyl)oxazolidine-3-carboxylate 
• 1005409-06-2 (S)-tert-butyl 2,2,4-trimethyl-4-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxazolidine-3-carboxylate 
• 1005407-69-1 1,1-dimethylethyl (4S)-2,2,4-trimethyl-4-[(2-{[4-(n-octyloxy)-3-(trifluoromethyl)phenyl]carbonyl}hydrazino)carbonyl]-1,3-oxazolidine-3-carboxylate 
• 1179522-57-6 1,1-dimethylethyl (2R,4S)-2-(1,1-dimethylethyl)-4-methyl-4-{5-[4-(n-octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1,3-oxazolidine-3-carboxylate 
• 1005407-72-6 1,1-dimethylethyl (4S)-2,2,4-trimethyl-4-{5-[4-(n-octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1,3-oxazolidine-3-carboxylate 
• 1179522-56-5 1,1-dimethylethyl (2R,4S)-2-(1,1-dimethylethyl)-4-methyl-4-[(2-{[4-(n-octyloxy)-3-(trifluoromethyl)phenyl]carbonyl}-hydrazino)carbonyl]-1,3-oxazolidine-3-carboxylate 

Relevant academic research and scientific papers

Discovery of clinical candidate GSK1842799 As a selective S1P1 receptor agonist (prodrug) for multiple sclerosis

To develop effective oral treatment for multiple sclerosis (MS), we discovered a series of alkyl-substituted biaryl amino alcohols as selective S1P1 modulators. One exemplar is (S)-2-amino-2-(5-(4-(octyloxy)-3- (trifluoromethyl)phenyl)-1,3,4-th

Development of a fully telescoped synthesis of the S1P1 agonist GSK1842799

The development of a fully telescoped synthesis of the potent and selective S1P1 agonist GSK1842799 is described. Key features in the synthesis, which has been implemented on a multikilogram scale, include a nucleophilic aromatic substitution to install a

THE HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR

The invention relates to the compound (2S)-2-amino-2-{5-[4-(octyloxy)-3- (trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate, processes for its preparation, pharmaceutical compositions containing them and its use in the treatment of c

CHEMICAL COMPOUNDS

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, a